Introduction
Stenotrophomonas maltophilia (formerly Xanthomonas maltophilia) is a Gram-negative, non-fermentative bacillus that is ubiquitous in the environment. 1 It is increasingly recognized as a cause of serious infections in hospitalized patients. [2] [3] [4] [5] [6] [7] [8] [9] These infections are particularly common in patients who are immunocompromised due to underlying illness. Meningitis secondary to S. maltophilia has rarely been described. We report a patient who developed meningitis, and review 15 previously described cases from the literature.
The case
A 30-year-old man was admitted to our neurosurgery intensive care unit (ICU). He had undergone surgery twice at another hospital for subdural hematoma and left parietal contusion following a car accident. On admission to our clinic the patient was unconscious, pupils were anisocoric, and his response to pain was extensor. Assuming a cerebral herniation, the right temporoparietal hematoma was emptied with a craniotomy.
Two days after surgery, the patient had a fever of 38.9 8C. The laboratory findings on the same day were as follows: white blood cell (WBC) count 22.3 Â 10 9 /l, C-reactive protein (CRP) 161 mg/dl (normal value <0.5 mg/dl), hemoglobin 11 mg/dl, hematocrit 34%, platelet count 145 Â 10 9 /l, urea 15 mg/dl, and creatinine 1.1 mg/dl. Cultures were obtained and vancomycin 2 Â 1 g and meropenem 3 Â 1 g were initiated empirically. We could not count the number of cells in the cerebrospinal fluid (CSF) because of the cerebral hemorrhage. The patient remained febrile, and on the third day of treatment CSF culture yielded a positive signal. Gramnegative bacilli were seen on Gram stain of the CSF culture. On the following day, the Gram-negative bacilli were identified as S. maltophilia by conventional procedures. The strain was highly resistant and only sensitive to TMP-SMX and ciprofloxacin. We confirmed the result as S. maltophilia by mini API system (BioMérieux). Other cultures did not yield meaningful results. Treatment was switched to TMP-SMX (trimethoprim 15 mg/kg) and ciprofloxacin 2 Â 400 mg therapy on the fourth day of meropenem and vancomycin treatment, while the patient was still febrile.
On the third day of new combination therapy, his fever had subsided to 37.4 8C, and the acute phase results were as follows: WBC 16.4 Â 10 9 /l and CRP 71 mg/dl. On the fourth day of therapy we obtained CSF for control culture, but it yielded no positive result. At the end of two weeks, the patient was conscious, afebrile, and discharged from the ICU.
Discussion
S. maltophilia, a Gram-negative rod, was first identified in 1958 by Hugh and Ryschenkow. 1 Although S. maltophilia is a rare cause of community-acquired infections, it is increasingly recognized as an emerging cause of hospital-acquired infection, particularly among severely debilitated or immunosuppressed patients.
2 S. maltophilia can cause a wide variety of infections, including bacteremia, endocarditis, pneumonia, pyelonephritis, cellulitis, and meningitis. 3 Treatment of patients infected with S. maltophilia is generally complicated because of high resistance to multiple antibiotics. 4 Meningitis due to S. maltophilia is rarely seen, and there are only 15 cases reported in the literature (Table 1) . Meningitis developed after a neurosurgical procedure in nine of these 15 patients, and six were community-acquired. 2, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Four patients were children and the infection source in three of them was community. Three patients died despite medical therapy, but none of them received appropriate antibiotics. Our case was also a nosocomial meningitis, and probably acquired during the neurosurgical procedures.
Caylan et al., 14 reported the risk factors predisposing for S. maltophilia meningitis, as prematurity, neurosurgical procedures (especially shunts or drains), intracranial hemorrhage, and malignancy. Carbapenem treatment has also been suggested as a risk factor for infection/colonization with S. maltophilia. 17 Risk factors for our patient were parallel to these reports: neurosurgical procedure application and carbapenem use.
S. maltophilia is resistant to several antibiotics used empirically for nosocomial infections. Inducible beta-lactamase activity (including L1 metallo-b-lactamase and L2 serine-b-lactamase), efflux mechanism, aminoglycoside modifying enzyme activity, biofilm formation, and production of 18 Nicodemo and Paez 18 suggested TMP-SMX as the empirical choice for clinically suspected S. maltophilia infections and as the treatment of choice for culture-proven infections by this agent. In the reported cases, TMP-SMX was the agent most used. Our strain was resistant to imipenem, meropenem, amikacin, ceftazidime, piperacillin/tazobactam, and ampicillin/sulbactam and sensitive to TMP-SMX and ciprofloxacin. There is not much information in the literature on combination therapy against S. maltophilia. Zelenitsky et al. 19 reported that TMP-SMX combined with other antimicrobial agents, such as ceftazidime, produced a net bacterial kill and provided significant benefit over monotherapy. We also used TMP-SMX and combined it with ciprofloxacin for our patient.
In conclusion, S. maltophilia is an emerging pathogen for nosocomial infections. Meningitis due to S. maltophilia is rare and experience is limited. Physicians must be alert to S. maltophilia, especially in the case of meningitis that develops after a neurosurgical procedure that does not respond to empirical treatment. When S. maltophilia is obtained from culture, empirical treatment must involve TMP-SMX, and the treatment must be corrected as per antibiogram results, because resistance to TMP-SMX has also been reported as an increasing problem for this pathogen.
